Nifurtimox
![Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set](http://data.docslib.org/img/264x/135084d885a0ce0d8ef8f9f83426c79a.webp)
Top View
- Final1-Aritmo-Final-Report-V2-0Final.Pdf
- Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies
- Impact of Diseases
- Leishmania Infantum Isolates Exhibit High Infectivity and Reduced Susceptibility to Amphotericin B
- Leishmania Infantum Isolates Exhibit
- The Selection and Use of Essential Medicines
- Drugs for Parasitic Infections (2013 Edition)
- Engineering Oral and Parenteral Amorphous Amphotericin B Formulations Against Experimental Trypanosoma Cruzi Infections
- Acknowledgements Funding Transparency Declarations in Vitro
- Identification of Trypanosoma Cruzi Growth Inhibitors with Activity In
- In Vitro Benznidazole and Nifurtimox Susceptibility Profile of Trypanosoma Cruzi Strains Belonging to Discrete Typing Units
- LAMPIT Safely and Effectively
- Guidelines for Prevention and Treatment of Opportunistic
- Monitoring the Use of Nifurtimox-Eflornithine Combination Therapy (NECT) in the Treatment of Second Stage Gambiense Human African Trypanosomiasis
- Pharmacometabolomics of Meglumine Antimoniate in Patients with Cutaneous Leishmaniasis
- Amebic Meningoencephalitis.Qxd
- Biopharmaceutical Optimization in Neglected Diseases for Paediatric Patients by Applying the Provisional Paediatric Biopharmaceutical Classification System
- And Body Weight-Adjusted Dosing in Patients with Chagas Disease